Navigating the
Pharma/Biotec
IP Ecosystem in Europe

Navigating the
Pharma/Biotec
IP Ecosystem in Europe

The changing intellectual property (IP) landscape for pharmaceuticals has been debated by biosimilars and generic drug makers for a number of years. The Supplementary Protection Certificate (SPC) manufacturing waiver, which will put an end to the legal requirement to delocalise pharmaceutical production outside of Europe has been lauded as a positive step for competition and security of supply of medicines at the conference.

There are still concerns that remain unanswered for some, particularly  with variables such as the patent linkage process, which continues to be a barrier to competition and timely access to generic and biosimilar medicines in several EU member states despite the clear decision 10 years ago to ban this anti-competitive practice. There have also been questions as to why the European patent system has failed to address documented problems with patent quality in relation to the pharmaceutical sector. Failing to address this issue undermines the credibility of the system and risks delaying access to medicines.

Pharmaceutical Patent experts at NLO will be answering your most pressing questions, which will specifically cater for the Chinese market on the 19th November 2021. To secure your place, please register below.

If you would like to attend or if you would like more information about hosting a discussion, please contact us.

    I agree to the the terms set out with Insight IP’s Privacy Policy
    I agree

    Contact

    Insight IP Ltd,
    Longcroft House,
    2-8 Victoria Avenue,
    London, EC2M 4NS
    T: +44 (0) 207 846 0283
    E: info@insightip.co.uk

    Copyright © 2021 insightip.co.uk All Rights Reserved. Web Design by Intuitive Web Design